CTNM vs DRMA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

CTNM

70.7
AI Score
VS
CTNM Wins

DRMA

61.1
AI Score

Investment Advisor Scores

CTNM

71score
Recommendation
BUY

DRMA

61score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CTNM DRMA Winner
Net Income -42.26M -4.81M DRMA
Operating Income -50.89M -4.94M DRMA
ROE -21.3% -138.0% CTNM
ROA -19.9% -90.5% CTNM
Total Assets 212.85M 5.32M CTNM
Cash 21.94M 4.41M CTNM
Current Ratio 20.69 3.40 CTNM
Free Cash Flow -33.36M -5.01M DRMA

Relative Price Performance (Last 90 Days)

CTNM 1M: -21.5% · 3M: -14.0% DRMA 1M: -14.6% · 3M: -17.2%

Current Technical Phase

CTNM

Markdown
Sell / avoid

Price below a falling SMA50 (slope -1.8%), weak momentum, RSI 43

RSI (14): 42.9 · Price: $12.99

DRMA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.5%), weak momentum, RSI 40

RSI (14): 40.0 · Price: $1.11

Fundamentals Snapshot

Metric CTNM DRMA
Market Cap — —
Forward P/E -6.8 -0.8
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin — —
Operating Margin 0.0% 0.0%
EPS -1.72 -4.20
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CTNM is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.